Insights

Innovative Vaccine Platform Vivaldi Biosciences utilizes the Delta NS1 platform, a versatile and self-adjuvanting nasal spray vaccine technology, which provides rapid and broad protective immunity. This innovative approach presents opportunities for partnerships or licensing with organizations seeking advanced vaccine delivery technologies.

Pipeline Expansion Potential With a strong pipeline including a Phase 2 universal influenza vaccine and upcoming trials for a combined influenza and COVID-19 vaccine, Vivaldi offers multiple opportunities for OEM manufacturing, clinical trial support, and commercial distribution alliances.

Recent Investment Boost Recent funding from Flu Lab and participation in major vaccine congresses highlight the company's growing recognition and validation within the biotech community, indicating a favorable environment for strategic collaborations or capital investment opportunities.

Focused Viral Disease Solutions Vivaldi specializes in nasal spray vaccines targeting epidemic and pandemic respiratory viruses, aligning well with government agencies and healthcare providers seeking effective, easy-to-administer immunization solutions to enhance epidemic preparedness.

Market Differentiation As a clinical-stage biotech with a unique focus on universal flu and Covid-19 combination vaccines, Vivaldi offers partners the chance to differentiate in a competitive market by leveraging its innovative technology and sustainable pipeline for future vaccine developments.

Vivaldi Biosciences Tech Stack

Vivaldi Biosciences uses 8 technology products and services including Google Hosted Libraries, RSS, Webpack, and more. Explore Vivaldi Biosciences's tech stack below.

Google Hosted Libraries

Content Delivery Network

RSS

Content Management System

Webpack

Development

DreamWeaver

Editors

Stimulus

Javascript Frameworks

Choices

Javascript Libraries

Modernizr

Javascript Libraries

SWFObject

Miscellaneous

Vivaldi Biosciences Email Formats	Example	Percentage
First.Last@vivaldibiosciences.com	John.Doe@vivaldibiosciences.com	50%
First.Last@vivaldibiosciences.com	John.Doe@vivaldibiosciences.com	50%

Vivaldi Biosciences Email Formats

Example

Percentage

First.Last@vivaldibiosciences.com

John.Doe@vivaldibiosciences.com

50%

First.Last@vivaldibiosciences.com

John.Doe@vivaldibiosciences.com

50%

Frequently Asked Questions

Where is Vivaldi Biosciences's headquarters located?

Vivaldi Biosciences's main headquarters is located at 3185-a Rampart Road Fort Collins, Colorado 80523 United States. The company has employees across 2 continents, including North AmericaEurope.

What is Vivaldi Biosciences's phone number?

You can contact Vivaldi Biosciences's main corporate office by phone at

+1-970-492-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Vivaldi Biosciences's official website and social media links?

Vivaldi Biosciences's official website is vivaldibiosciences.com and has social profiles on LinkedIn Crunchbase.

What is Vivaldi Biosciences's SIC code NAICS code?

Vivaldi Biosciences's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Vivaldi Biosciences have currently?

As of February 2026, Vivaldi Biosciences has approximately 11 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer, Director: B. W.Chief Executive Officer: B. W.Vice President Of Research And Development: A. A.. Explore Vivaldi Biosciences's employee directory with LeadIQ.

What industry does Vivaldi Biosciences belong to?

Vivaldi Biosciences operates in the Biotechnology Research industry.

What technology does Vivaldi Biosciences use?

Vivaldi Biosciences's tech stack includes Google Hosted LibrariesRSSWebpackDreamWeaverStimulusChoicesModernizrSWFObject.

What is Vivaldi Biosciences's email format?

Vivaldi Biosciences's email format typically follows the pattern of First.Last@vivaldibiosciences.com. Find more Vivaldi Biosciences email formats with LeadIQ.

How much funding has Vivaldi Biosciences raised to date?

As of February 2026, Vivaldi Biosciences has raised $2M in funding. The last funding round occurred on Jul 08, 2010 for $2M.

Vivaldi Biosciences

Q: How many employees does Vivaldi Biosciences have currently?

Vivaldi Biosciences has approximately 11 employees.

Q: What technology does Vivaldi Biosciences use?

Vivaldi Biosciences's tech stack includes RSS, Element UI, Google Hosted Libraries, jQuery, Adobe Fonts.

Biotechnology ResearchColorado, United States11-50 Employees

Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. 
Vivaldi’s DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. 
Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.

Insights

Similar companies to Vivaldi Biosciences

Medpace

Covance

SGS

Eurofins

Thermo Fisher Scientific

WuXi AppTec

Catalent Pharma Solutions

Lonza

Charles River Laboratories